25 Jul 2019 --- The US Food and Drug Administration (FDA) has issued a warning letter to US-based Curaleaf Inc., for illegally selling unapproved products containing cannabidiol (CBD) online. The company has made unsubstantiated claims that its products treat cancer, Alzheimer’s disease, opioid withdrawal, pain and pet anxiety, among other conditions or diseases, according to the FDA. “As we examine potential regulatory pathways for the lawful marketing of products with CBD, protecting and promoting public health remains our top priority,” says Acting FDA Commissioner Ned Sharpless, MD.